If we push research forward with tireless determination, it’s because we know that the benefits of our efforts will reach our children and all individuals affected by a SLC6A1 mutation. The sooner we can provide targeted therapies to our loved ones, the greater the chance of significantly and sustainably improving their quality of life.
That is why ours is a race against time.
We warmly welcome you to SLC6A1 Switzerland
WE ARE THE NON-PROFIT PATIENT ORGANIZATION DEDICATED TO THE SLC6A1 MUTATION IN SWITZERLAND AND A FOUNDING MEMBER OF THE SLC6A1 EUROPE ALLIANCE.
INFORMATION
​SLC6A1 Switzerland shares up-to-date knowledge about the SLC6A1 mutation.
SUPPORT
​
SLC6A1 Switzerland offers support to affected individuals and their families.
RESEARCH​
​
SLC6A1 Switzerland promotes research with the aim of developing targeted therapeutic solutions.
What is the SLC6A1 mutation?
The SLC6A1 mutation is a rare disease that affects approximately 1 in 38,000 people.
The SLC6A1 gene encodes a protein called GAT-1, which is located in the membranes of neurons and astrocytes and is responsible for the reuptake of the neurotransmitter GABA (gamma-aminobutyric acid).
When the SLC6A1 gene is mutated, the GAT-1 protein does not function properly.
This can lead to epilepsy, cognitive delay, behavioural challenges, insomnia, autism and a range of other symptoms.
​
Our mission
Raise awareness. Support research. Stand by families.
At SLC6A1 Switzerland, we are committed to giving visibility to this rare disease, providing support to affected families, and advancing research toward increasingly targeted and effective therapies.
SLC6A1 EUROPE
We founded it and watched it strengthen at a pace beyond all our expectations. Today, we look at it with pride and confidence: SLC6A1 Europe is ready to grow.
SLC6A1 Switzerland is proud to be a founding member of the SLC6A1 Europe Alliance.
In August 2025, the first European SLC6A1 Symposium took place in Lisbon. The event brought together families affected by the mutation, researchers, and representatives from the pharmaceutical industry committed to understanding and addressing the disorder.
The day after the symposium, still in Lisbon, our network of researchers met, under the guidance of Elena Bossi, University of Insubria, and Mouhamed Alsaqati, Newcastle University, to coordinate future research projects.
To contact the coordinators of the SLC6A1 Europe Alliance: